HeartBeam Names Timothy Cruickshank as Chief Financial Officer
HeartBeam (NASDAQ: BEAT) has appointed Timothy Cruickshank as its new Chief Financial Officer, effective immediately. Cruickshank brings over 15 years of public company experience, focusing on growing businesses with disruptive technologies. He succeeds Richard Brounstein, who retired in February.
HeartBeam has developed a cable-free, credit card-sized device that captures the heart's electrical signals in three dimensions, capable of synthesizing a 12-lead ECG. The company's first 510(k) submission for this proprietary technology is currently under FDA review. HeartBeam holds 13 US patents and 4 international patents supporting the technology.
Cruickshank, 43, previously served as CFO at ImpediMed, where he led the company's transformation from a traditional medical device company to a medical technology company with a high-margin SaaS business model.
HeartBeam (NASDAQ: BEAT) ha nominato Timothy Cruickshank come nuovo Chief Financial Officer, con effetto immediato. Cruickshank porta con sé oltre 15 anni di esperienza in aziende pubbliche, concentrandosi sulla crescita di attività con tecnologie dirompenti. Sostituisce Richard Brounstein, che si è ritirato a febbraio.
HeartBeam ha sviluppato un dispositivo senza cavi, delle dimensioni di una carta di credito che cattura i segnali elettrici del cuore in tre dimensioni, in grado di sintetizzare un ECG a 12 derivazioni. La prima richiesta 510(k) dell'azienda per questa tecnologia proprietaria è attualmente al vaglio della FDA. HeartBeam detiene 13 brevetti statunitensi e 4 brevetti internazionali a sostegno della tecnologia.
Cruickshank, 43 anni, ha precedentemente ricoperto il ruolo di CFO in ImpediMed, dove ha guidato la trasformazione dell'azienda da produttore tradizionale di dispositivi medici a un'azienda di tecnologia medica con un modello di business SaaS ad alta marginalità.
HeartBeam (NASDAQ: BEAT) ha nombrado a Timothy Cruickshank como su nuevo Director Financiero, con efecto inmediato. Cruickshank aporta más de 15 años de experiencia en empresas públicas, centrándose en el crecimiento de negocios con tecnologías disruptivas. Sucede a Richard Brounstein, quien se jubiló en febrero.
HeartBeam ha desarrollado un dispositivo sin cables, del tamaño de una tarjeta de crédito que captura las señales eléctricas del corazón en tres dimensiones, capaz de sintetizar un ECG de 12 derivaciones. La primera presentación 510(k) de la empresa para esta tecnología patentada está actualmente en revisión por la FDA. HeartBeam tiene 13 patentes en EE. UU. y 4 patentes internacionales que respaldan la tecnología.
Cruickshank, de 43 años, se desempeñó anteriormente como CFO en ImpediMed, donde lideró la transformación de la empresa de una compañía de dispositivos médicos tradicional a una empresa de tecnología médica con un modelo de negocio SaaS de alta rentabilidad.
HeartBeam (NASDAQ: BEAT)가 Timothy Cruickshank을 새로운 최고 재무 책임자로 즉시 임명했습니다. Cruickshank는 방해가 되는 기술로 비즈니스를 성장시키는 데 초점을 맞춘 15년 이상의 공공 회사 경험을 가지고 있습니다. 그는 2월에 은퇴한 Richard Brounstein을 대신합니다.
HeartBeam은 케이블 없는 신용 카드 크기의 장치를 개발하였으며, 심장의 전기 신호를 3차원으로 캡처하여 12유도 ECG를 합성할 수 있습니다. 이 회사의 독점 기술에 대한 첫 번째 510(k) 제출이 현재 FDA 심사를 받고 있습니다. HeartBeam은 이 기술을 지원하는 미국 특허 13개와 국제 특허 4개를 보유하고 있습니다.
Cruickshank(43세)는 이전에 ImpediMed의 CFO로 재직하며 전통적인 의료 기기 회사에서 높은 마진의 SaaS 비즈니스 모델을 가진 의료 기술 회사로의 변화를 이끌었습니다.
HeartBeam (NASDAQ: BEAT) a nommé Timothy Cruickshank en tant que nouveau directeur financier, avec effet immédiat. Cruickshank apporte plus de 15 ans d'expérience dans des entreprises publiques, en se concentrant sur la croissance d'entreprises avec des technologies perturbatrices. Il succède à Richard Brounstein, qui a pris sa retraite en février.
HeartBeam a développé un dispositif sans fil, de la taille d'une carte de crédit qui capture les signaux électriques du cœur en trois dimensions, capable de synthesiser un ECG à 12 dérivations. La première soumission 510(k) de l'entreprise pour cette technologie propriétaire est actuellement en attente d'examen par la FDA. HeartBeam détient 13 brevets américains et 4 brevets internationaux soutenant la technologie.
Cruickshank, 43 ans, a précédemment occupé le poste de CFO chez ImpediMed, où il a dirigé la transformation de l'entreprise d'un fabricant traditionnel de dispositifs médicaux à une entreprise de technologie médicale avec un modèle commercial SaaS à forte marge.
HeartBeam (NASDAQ: BEAT) hat Timothy Cruickshank als neuen Finanzvorstand ernannt, der sofort in Kraft tritt. Cruickshank bringt über 15 Jahre Erfahrung in börsennotierten Unternehmen mit, wobei er sich auf das Wachstum von Unternehmen mit disruptiven Technologien konzentriert. Er tritt die Nachfolge von Richard Brounstein an, der im Februar in den Ruhestand gegangen ist.
HeartBeam hat ein kabelloses, kreditkarten großes Gerät entwickelt, das die elektrischen Signale des Herzens in drei Dimensionen erfasst und in der Lage ist, ein 12-Kanal-EKG zu synthetisieren. Der erste 510(k)-Antrag des Unternehmens für diese proprietäre Technologie befindet sich derzeit in der Prüfung durch die FDA. HeartBeam hält 13 US-Patente und 4 internationale Patente, die die Technologie unterstützen.
Cruickshank, 43, war zuvor CFO bei ImpediMed, wo er das Unternehmen von einem traditionellen Medizinproduktehersteller zu einem Medizintechnologieunternehmen mit einem hochmargigen SaaS-Geschäftsmodell transformierte.
- Appointment of experienced CFO Timothy Cruickshank with 15+ years of public company experience
- Development of innovative cable-free, credit card-sized ECG device
- First 510(k) submission for proprietary technology under FDA review
- Strong patent portfolio with 13 US and 4 international patents
- None.
Seasoned MedTech Leader with Proven Track Record of Strategic Planning, Financial Stewardship and Commercial Success
“Tim has an outstanding record of delivering results and creating value and will be a strong partner in ensuring we have a solid financial position as we strive to make our vision to transform the monitoring and detection of cardiac conditions a reality,” said Branislav Vajdic, PhD, Chief Executive Officer and Founder of HeartBeam. “We thank Rick for his leadership over the past 9 years as he worked tirelessly to establish the strong financial foundation for the company which will continue to serve us well moving forward.”
HeartBeam has developed a cable-free, credit card-sized device that captures the heart’s electrical signals from three dimensions and is designed to be capable of synthesizing a 12-lead ECG. The Company’s first 510(k) submission for its proprietary technology is currently under review with the FDA and is the cornerstone submission upon which future submissions will be based. The Company has 13 issued US patents and 4 issued international patents supporting the underlying technology.
“The ability of HeartBeam’s unique technology to unlock actionable heart intelligence from three dimensions for a range of cardiac conditions is truly compelling to me,” said Mr. Cruickshank. “I am excited to join the Company at this pivotal time and look forward to working with the team to commercialize this impactful innovation, drive financial excellence and expand our impact to ultimately improving cardiac care for patients.”
Mr. Cruickshank, age 43, was a financial executive of ImpediMed since 2008 and served as CFO from October 2019 through March 2024. ImpediMed is a medical technology company that designs and manufactures medical devices and software services employing its pioneering bioimpedance spectroscopy (BIS) technology for multiple indications including heart failure, protein calorie malnutrition, and lymphedema within oncology. During Mr. Cruickshank’s time at ImpediMed, he spearheaded the evolution of the company from a traditional medical device company to a medical technology company with a high margin Software-as-a-Service (SaaS) business model, through the launch of the SOZO® Digital Health Platform. He received a Master of Business Administration from Keller Graduate School of Management and a Bachelor of Science in Accounting from
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The Company is creating the first ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. The Company holds 13 US and 4 international issued patents related to technology enablement.
For additional information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910912946/en/
Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us
Media Contact:
media@heartbeam.com
Source: HeartBeam, Inc.
FAQ
Who is the new CFO of HeartBeam (BEAT)?
What is HeartBeam's (BEAT) main product under development?
What is the current status of HeartBeam's (BEAT) FDA submission?
How many patents does HeartBeam (BEAT) hold for its technology?
